InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
4,967.23
(
-0.88%
)
US TECH 100
16,557.60
(
-2.24%
)
Dow Jones
37,986.40
(
0.56%
)
Brent Oil
86.64
(
0.25%
)
Bitcoin
64,319.50
(
1.27%
)
Post# of 45083
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Let's Roll

Send PM Follow Ignore
Followers 883
Posts 304355
Boards Moderated 5
Alias Born 06/09/2006

Let's Roll

Re: None

Thursday, 03/23/2017 9:20:23 AM

Thursday, March 23, 2017 9:20:23 AM

Post# of 45083
$RGBP "This is an extremely exciting time for Regen as we are moving the company dynamically forward. The ChemDiv studies are the gateway to potentially strong relationships, with one or more large pharmaceutical companies that have already express interest in our NR2F6 small molecule therapeutic models for treating cancer and arthritis immunologically. ChemDiv, Inc. is an elite contract research organization and we are enthusiastic about their involvement with our small molecule drug development program," stated David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. "Their professionalism and deep knowledge of this space makes it easy for us to oversee this process and allows us to strategically plan next steps."

https://finance.yahoo.com/news/regen-biopharma-inc-provides-nr2f6-120000232.html

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up